VIC Technology Venture Development™ Forms New Portfolio Company, Solenic Medical, Inc.

Company co-founded with David Greenberg, M.D. and Rajiv Chopra Ph.D., developers of a novel treatment for prosthetic joint infection.

 

DALLAS, TX – VIC Technology Venture Development, LLC (VIC) has announced that it has formed Solenic Medical, Inc. The company was established to develop and commercialize a method for treating prosthetic joint infection (PJI) based on technology exclusively licensed from University of Texas Southwestern Medical Center (UTSW). The patent-pending technology offers an approach for the eradication of biofilm from metallic implants. Advantages include non-invasive treatment of PJI through selective targeting of biofilms.

James Y. Lancaster, Managing Director of VIC’s Texas Branch, is serving as interim CEO of Solenic Medical. Mr. Lancaster provides management expertise in the areas of business development, technology commercialization, team formation, and corporate strategic planning. He will also oversee the development and execution of key commercial milestones, funding, and, ultimately, the recruitment of a permanent CEO for the company.

“This is an exciting technology that solves a huge problem in the fast-growing field of medical implants where humans are living longer lives,” said Mr. Lancaster. “Driven both by the growing population and patients’ desires to maintain an active lifestyle, there is a huge need to provide solutions to prosthetic joint infections that risk the success of increasingly common surgical procedures.”

Each year in the United States, over 1 million total knee and hip replacements are performed, and these operations are projected to increase by 637% and 174% respectively by the year 2030. Prosthetic joint infection (PJI) is one of the most serious complications in the field of arthroplasty. Currently, treatment of PJI can involve a two-stage revision requiring two additional surgeries and weeks of antibiotic treatment. While effective, it is associated with a significant negative impact on a patient’s quality of life, and is very expensive. The projected total annual cost to treat patients with PJIs in the U.S. in 2020 is a staggering $1.6 billion, representing a major cost to the healthcare system.

A major impediment to effective treatment of PJI is the presence of biofilm, a thin film produced by bacteria that forms a protective shield around the joint and impairs the effectiveness of both antibiotics and the immune response system. Biofilm is associated with infections of many widely used medical implants such as catheters, mechanical heart valves, intrauterine devices, and prosthetic joints. The inability to eradicate biofilm is the primary reason for surgical replacement of an implant being the standard care practice for PJI.

The Greenberg and Chopra laboratories at UTSW discovered a novel method for treating PJI that is completely non-invasive and selective to biofilms. The method utilizes alternating magnetic fields (AMF) to achieve temperatures on the surface of metal implants sufficient to disrupt biofilm and kill bacteria.

“We believe that a non-invasive approach utilizing AMF either alone or in concert with antibiotics could prevent multiple surgeries and allow the patient to keep their original implant. This could have a significant impact on the patient’s quality of life as well as provide a significant cost savings to the health care system,” says Dr. Greenberg, an Associate Professor of Internal Medicine and Microbiology at UT Southwestern and a co-founder of Solenic Medical and co-inventor on the underlying technology.

Dr. Greenberg and Dr. Chopra are unpaid consultants who own Founder’s Stock in Solenic Medical, Inc. UT Southwestern Medical Center owns Licensor’s stock in Solenic Medical Inc.

Solenic Medical, Inc. is a medical device company founded in 2019 to develop and commercialize a method for preventing prosthetic joint infection (PJI) based on technology exclusively licensed from University of Texas Southwestern Medical Center (UTSW). The patent-pending technology offers an apparatus for the eradication of biofilm from metallic implants. Advantages include non-invasive treatment of PJI through selective targeting of biofilms. Solenic Medical, Inc. is a VIC Technology Venture Development™ portfolio company. 

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 15 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

CardioWise, Inc. Named a Top-Ten Finalist in Best Cardiovascular Digital Diagnostic Category by UCSF Health Hub

CardioWise™ is commercializing patented, Cardiac Computed Tomography (CT) machine learning analysis software, SQuEEZ™, which produces a quantified image model of the human heart.

 

UCSF Digital Health Awards 2019FAYETTEVILLE, AR – October 8, 2019 – The University of California San Francisco (UCSF) Health Hub has selected CardioWise, Inc. a Digital Health Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic category. The goal of UCSF Digital Health Awards was to select companies that promote faster, better, more cost-effective healthcare by improving outcomes such as shorter hospital stays, reduced patient and insurer costs, faster cures, and happier doctors and patients. The awards are intended to showcase new technologies that are dramatically improving healthcare through innovative means, to benefit society and to reduce the onerous cost burden. Over 500 companies participated, representing thirteen categories, with over 100 judges.

As described by the Health Hub: “The goal of the UCSF Digital Health Awards is to ultimately help patients access amazing innovations by recognizing and awarding the great companies with the best in-market digital products and services. The live event, held in San Francisco on October 10, 2019, will be live-streamed and is the first of its kind patient and clinician oriented awards event.”

“We are proud to have been chosen as a Top Ten Finalist in the Cardiovascular Digital Diagnostic category of the 2019 UCSF Digital Health Awards,” said Jack Coats, CEO of CardioWise. “UCSF is recognized as an expert in digital health and has a superlative reputation, currently 7th in the US News national hospital rankings. For a startup company like CardioWise to have been chosen from over 500 applications by a team of prestigious judges, all organized by UCSF, is truly an honor and a tribute to our fine development team led by Geoffrey Dalbow, CardioWise CTO.”

Top 10 companies in each category can be seen here: https://www.healthhubsf.org/awards/quarter-finalists

CardioWise™ is commercializing patented, non-invasive Cardiac CT analysis software that produces a quantified 4D image model of the human heart, called Stretch Quantifier for Endocardial Engraved Zones™ (SQuEEZ™). CardioWise heart analysis software combined with cardiac CT is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis. CardioWise™ is a VIC Technology Venture Development™ portfolio company.

Zebra Analytix Receives Phase I SBIR Award from the National Institutes of Health

Proin quis magna sed ipsum venenatis ultricies. Sed maximus at lacus ac egestas. Vestibulum porttitor nulla a metus bibendum, non laoreet sapien venenatis. In tempor pellentesque mauris a aliquet. Duis ac nibh auctor dui lacinia laoreet. Mauris posuere, massa vel vehicula luctus, neque ligula dapibus ante, a posuere elit lorem non nisi. Mauris sit amet leo vehicula enim iaculis ultricies id id mauris. Aliquam erat volutpat. Interdum et malesuada fames ac ante ipsum primis in faucibus. Sed non mollis nisl. Vestibulum id dui ac tortor finibus venenatis. Nullam pharetra interdum congue. Maecenas at imperdiet risus, non accumsan lorem. Nullam elementum mauris diam, vel iaculis erat tincidunt nec. Nunc porta maximus sem, ut faucibus augue tristique non.

Continue reading

Green light for £100m Clydeside resi development

Jupiter X develops innovative solutions to build critical infrastructure and landmark projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in […]

Continue reading

Green light for £100m Clydeside resi development

Jupiter X develops innovative solutions to build critical infrastructure and landmark projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in […]

Continue reading

Green light for £100m Clydeside resi development

Jupiter X develops innovative solutions to build critical infrastructure and landmark projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in […]

Continue reading

Green light for £100m Clydeside resi development

Jupiter X develops innovative solutions to build critical infrastructure and landmark projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in […]

Continue reading

Green light for £100m Clydeside resi development

Jupiter X develops innovative solutions to build critical infrastructure and landmark projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in […]

Continue reading

Crossrail CEO: Why are we on our third this year?

Jupiter X develops innovative solutions to build critical infrastructure and landmark projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in […]

Continue reading

Hawk Plant jobs saved as Plantforce acquires Hinkley assets

Jupiter X develops innovative solutions to build critical infrastructure and landmark projects. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in […]

Continue reading